Divi’s Laboratories, a heavyweight in India’s pharmaceutical manufacturing sector, has entered into a long-term supply agreement with a global pharmaceutical firm to manufacture and deliver advanced intermediates. While the identity of the partner remains undisclosed, the deal is expected to generate significant revenue in the coming years. Concurrently, the company announced plans for a Rs. 650–700 crore investment to expand its manufacturing capacity, fully funded through internal accruals.